Exercise B-Claim
training I-Claim
to I-Claim
improve I-Claim
cardiovascular I-Claim
fitness I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
management I-Claim
of I-Claim
lymphoma I-Claim
patients I-Claim
. I-Claim

For B-Claim
men I-Claim
with I-Claim
localised I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
surgery I-Claim
provides I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
watchful I-Claim
waiting I-Claim
. I-Claim

In B-Claim
cachectic I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
oral I-Claim
melatonin I-Claim
20 I-Claim
mg I-Claim
at I-Claim
night I-Claim
did I-Claim
not I-Claim
improve I-Claim
appetite I-Claim
, I-Claim
weight I-Claim
, I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim

Results B-Claim
were I-Claim
comparable I-Claim
with I-Claim
or I-Claim
without I-Claim
a I-Claim
washout I-Claim
, I-Claim
supporting I-Claim
direct I-Claim
switching I-Claim
from I-Claim
anti-TNF I-Claim
therapy I-Claim
to I-Claim
abatacept I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

Genotypes B-Claim
of I-Claim
glutathione-related I-Claim
enzymes I-Claim
, I-Claim
especially I-Claim
GCLC I-Claim
, I-Claim
may I-Claim
be I-Claim
used I-Claim
as I-Claim
host I-Claim
factors I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
survival I-Claim
after I-Claim
platinum-based I-Claim
chemotherapy I-Claim
. I-Claim

Subcutaneous B-Claim
interleukin-2 I-Claim
and/or I-Claim
interferon-alfa I-Claim
provide I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
in I-Claim
metastatic I-Claim
renal I-Claim
cancers I-Claim
of I-Claim
intermediate I-Claim
prognosis I-Claim
, I-Claim
and I-Claim
they I-Claim
induce I-Claim
a I-Claim
significant I-Claim
risk I-Claim
of I-Claim
toxicity I-Claim
. I-Claim

We B-Claim
propose I-Claim
that I-Claim
VEGF I-Claim
expression I-Claim
levels I-Claim
in I-Claim
MPE I-Claim
could I-Claim
serve I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
marker I-Claim
for I-Claim
bevacizumab I-Claim
therapy I-Claim
. I-Claim

A B-Claim
colonic I-Claim
J-pouch I-Claim
may I-Claim
reduce I-Claim
excessive I-Claim
stool I-Claim
frequency I-Claim
and I-Claim
incontinence I-Claim
after I-Claim
anterior I-Claim
resection I-Claim
, I-Claim
but I-Claim
at I-Claim
the I-Claim
risk I-Claim
of I-Claim
evacuation I-Claim
problems I-Claim
. I-Claim

Anemia B-Claim
is I-Claim
an I-Claim
expected I-Claim
consequence I-Claim
of I-Claim
intensive I-Claim
chemotherapy I-Claim
regimens I-Claim
administered I-Claim
to I-Claim
patients I-Claim
with I-Claim
acute I-Claim
leukemia I-Claim
. I-Claim

Equivalence B-Claim
for I-Claim
three I-Claim
versus I-Claim
four I-Claim
cycles I-Claim
is I-Claim
claimed I-Claim
because I-Claim
both I-Claim
the I-Claim
upper I-Claim
and I-Claim
lower I-Claim
bounds I-Claim
of I-Claim
the I-Claim
80 I-Claim
% I-Claim
CL I-Claim
are I-Claim
less I-Claim
than I-Claim
5 I-Claim
% I-Claim
. I-Claim

Grade B-Premise
3/4 I-Premise
anemia I-Premise
developed I-Premise
in I-Premise
22 I-Premise
% I-Premise
of I-Premise
patients I-Premise
who I-Premise
received I-Premise
topotecan I-Premise
. I-Premise

Eighteen B-Premise
months I-Premise
after I-Premise
surgery I-Premise
, I-Premise
any I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
LAC I-Premise
or I-Premise
open I-Premise
colectomy I-Premise
favored I-Premise
LAC I-Premise
. I-Premise

Mean B-Premise
physical I-Premise
function I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
66 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
62·9-70·0 I-Premise
) I-Premise
in I-Premise
the I-Premise
90 I-Premise
mg I-Premise
group I-Premise
and I-Premise
68 I-Premise
points I-Premise
( I-Premise
64·6-71·4 I-Premise
) I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
of I-Premise
difference I-Premise
-6·6 I-Premise
to I-Premise
3·3 I-Premise
";" I-Premise
p=0·52 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
scores I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
arms I-Premise
at I-Premise
the I-Premise
fourth I-Premise
assessment I-Premise
( I-Premise
C I-Premise
= I-Premise
70.3 I-Premise
( I-Premise
19.6 I-Premise
) I-Premise
";" I-Premise
CP I-Premise
= I-Premise
72.8 I-Premise
( I-Premise
17.4 I-Premise
) I-Premise
) I-Premise
. I-Premise

No B-Premise
adverse I-Premise
effects I-Premise
were I-Premise
noted I-Premise
. I-Premise

The B-Premise
mean I-Premise
changes I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
trial I-Premise
group I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
: I-Premise
in I-Premise
the I-Premise
primary I-Premise
endpoints I-Premise
, I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
the I-Premise
secondary I-Premise
endpoints I-Premise
, I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
Glasgow I-Premise
Prognostic I-Premise
Score I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
IL-6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
1 I-Premise
case I-Premise
suffered I-Premise
from I-Premise
chest I-Premise
distress I-Premise
, I-Premise
3 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
acratia I-Premise
, I-Premise
and I-Premise
4 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
pyrexia I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
significantly I-Premise
more I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
for I-Premise
mood I-Premise
( I-Premise
p I-Premise
> I-Premise
.05 I-Premise
) I-Premise
or I-Premise
pain I-Premise
( I-Premise
p I-Premise
> I-Premise
.05 I-Premise
) I-Premise
levels I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
opportunistic I-Premise
infections I-Premise
. I-Premise

Seventy-two O
women O
( O
median O
age O
, O
60 O
y O
) O
were O
randomized O
in O
five O
hospitals O
. O

We O
aimed O
at O
investigating O
the O
efficacy O
, O
tolerability O
, O
and O
quality O
of O
life O
( O
QOL O
) O
of O
gemcitabine O
( O
GEM O
) O
compared O
with O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
in O
the O
salvage O
treatment O
of O
recurrent O
ovarian O
cancer O
. O

The O
primary O
objective O
was O
to O
compare O
progression-free O
survival O
( O
PFS O
) O
between O
the O
groups O
. O

The O
finding O
of O
a O
decrease O
in O
contralateral O
breast O
cancer O
incidence O
following O
tamoxifen O
administration O
for O
adjuvant O
therapy O
led O
to O
the O
concept O
that O
the O
drug O
might O
play O
a O
role O
in O
breast O
cancer O
prevention O
. O

Seventy-two O
women O
with O
breast O
cancer O
experiencing O
three O
or O
more O
hot O
flashes O
per O
day O
were O
randomly O
assigned O
to O
receive O
either O
TRUE O
or O
sham O
acupuncture O
. O

This O
study O
was O
registered O
on O
ClinicalTrials.gov O
. O

No O
patient O
received O
hormonal O
therapy O
. O

Participants O
were O
randomly O
allocated O
to O
receive O
either O
usual O
care O
or O
usual O
care O
plus O
group O
CBT O
( O
1:1 O
) O
. O

Analyses O
were O
by O
intention O
to O
treat O
. O

However O
, O
there O
is O
a O
wide O
heterogeneity O
in O
the O
clinical O
impact O
of O
hypothyroidism O
. O

There B-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
seen I-Premise
between I-Premise
groups I-Premise
for I-Premise
either I-Premise
activity I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
=-0.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
CI I-Premise
-1.0 I-Premise
to I-Premise
0.2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.17 I-Premise
) I-Premise
or I-Premise
profile I-Premise
scores I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
= I-Premise
-0.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.9 I-Premise
to I-Premise
0.1 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.13 I-Premise
) I-Premise
using I-Premise
this I-Premise
trial I-Premise
design I-Premise
, I-Premise
although B-Claim
post I-Claim
hoc I-Claim
power I-Claim
calculations I-Claim
suggests I-Claim
that I-Claim
65-175 I-Claim
would I-Claim
be I-Claim
needed I-Claim
per I-Claim
group I-Claim
to I-Claim
detect I-Claim
differences I-Claim
of I-Claim
this I-Claim
magnitude I-Claim
with I-Claim
sufficient I-Claim
precision I-Claim
. I-Claim

However O
, O
there B-Claim
was I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
secondary I-Claim
endpoints I-Claim
of I-Claim
clinically I-Claim
assessed I-Claim
OPS I-Claim
and I-Claim
DNA I-Claim
concentration I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
in I-Claim
H I-Claim
& I-Claim
N I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
CRT I-Claim
. I-Claim

In O
contrast O
, O
coping B-Premise
strategies I-Premise
( I-Premise
MAC I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

However O
, O
QOL B-Claim
scores I-Claim
were I-Claim
not I-Claim
significantly I-Claim
different I-Claim
among I-Claim
the I-Claim
regimens I-Claim
. I-Claim

While O
the B-Claim
short-term I-Claim
efficacy I-Claim
of I-Claim
degarelix I-Claim
and I-Claim
goserelin I-Claim
+ I-Claim
bicalutamide I-Claim
was I-Claim
the I-Claim
same I-Claim
in I-Claim
terms I-Claim
of I-Claim
TPV I-Claim
reduction I-Claim
, I-Claim
degarelix B-Claim
showed I-Claim
superiority I-Claim
in I-Claim
LUTS I-Claim
relief I-Claim
in I-Claim
symptomatic I-Claim
patients I-Claim
, I-Claim
which I-Claim
could I-Claim
highlight I-Claim
the I-Claim
different I-Claim
actions I-Claim
of I-Claim
these I-Claim
drugs I-Claim
on I-Claim
extrapituitary I-Claim
gonadotrophin-releasing I-Claim
hormone I-Claim
( I-Claim
GnRH I-Claim
) I-Claim
receptors I-Claim
in I-Claim
the I-Claim
bladder I-Claim
and/or I-Claim
the I-Claim
prostate I-Claim
. I-Claim

Finally O
, O
black B-Premise
women I-Premise
and I-Premise
white I-Premise
women I-Premise
were I-Premise
similar I-Premise
in I-Premise
terms I-Premise
of I-Premise
how I-Premise
they I-Premise
benefited I-Premise
from I-Premise
the I-Premise
MBAT I-Premise
intervention I-Premise
, I-Premise
even I-Premise
though I-Premise
white I-Premise
participants I-Premise
tended I-Premise
to I-Premise
have I-Premise
higher I-Premise
educational I-Premise
level I-Premise
and I-Premise
marital I-Premise
status I-Premise
. I-Premise

Nonetheless O
, O
no B-Claim
correlation I-Claim
between I-Claim
immediate I-Claim
lung I-Claim
expansion I-Claim
and I-Claim
clinical I-Claim
outcome I-Claim
was I-Claim
found I-Claim
in I-Claim
this I-Claim
study I-Claim
. I-Claim

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
9.2 I-Premise
months I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
and I-Premise
5.5 I-Premise
months I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
";" I-Premise
hazard B-Premise
ratio I-Premise
was I-Premise
0.50 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0002 I-Premise
. O

Patients B-Claim
with I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
do I-Claim
not I-Claim
have I-Claim
curative I-Claim
treatment I-Claim
options I-Claim
";" I-Claim
therefore O
, O
treatments O
should O
prolong O
survival O
and O
improve O
quality O
of O
life O
( O
QoL O
) O
. O

In O
this O
trial O
, O
histologic B-Claim
confirmation I-Claim
of I-Claim
N2 I-Claim
disease I-Claim
in I-Claim
the I-Claim
surgical I-Claim
and I-Claim
nonsurgical I-Claim
arms I-Claim
eliminated I-Claim
the I-Claim
usual I-Claim
biases I-Claim
from I-Claim
clinical I-Claim
staging I-Claim
. I-Claim

